ROCKVILLE, Md., March 8,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced it will participate in the following upcoming
investor conferences:
Barclays Global Healthcare Conference
Fireside
Chat Date: Wednesday, March 15,
2023
Fireside Chat Time: 5:00 p.m.
ET
Location: Miami, FL
BMO Biopharma Spotlight Series: Novel Technologies for the
Delivery of Genetic Medicines Panel: Innovative AAVs Targeting
Diverse Tissues
Panel Date: Tuesday, March 28, 2023
Panel Time: 9:00 a.m. ET
Location: Virtual
A live webcast of the presentation at the Barclays Global
Healthcare Conference can be accessed in the Investors section of
REGENXBIO's website at www.regenxbio.com. An archived replay of the
webcast will be available for approximately 30 days following the
presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from our internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301765374.html
SOURCE REGENXBIO Inc.